FDA’s Drug Naming Pilot Moves Forward, But Industry May Need Sweeter Rewards
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms lack explicit incentives to participate in the proposed self-evaluation, which will be discussed at a public meeting June 5-6.